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Introduction
Overuse of acute pain medication is a risk factor for
developing chronic headache.
Objectives
To investigate the association between the use of acute
anti-migraine medication as single analgesics (SA), com-
bination analgesics (CA) and triptanes (T) and the risk
for chronic headache in patients with episodic migraine.
Methods
We used data of the German Headache Consortium
(GHC) Study which is a population-based sample of
18,000 participants aged 18 to 65 years. Information
about headache features, frequency, use of medication
and years of education were collected at baseline (2003-
2005) and follow up one (t1) and two (t2) years after
baseline using mailed questionnaires. Participants with
prophylactic headache or other prophylactic pain medi-
cation were excluded (n=209). Primary outcome was
defined as incidence of chronic headache (any headache
on ≥15 days/month) at t1 or t2 in participants with
episodic migraine (≤14 days of migraine/month) at base-
line. We estimated odds ratios (OR) and 95%-confidence
intervals (95%-CI), adjusting for headache days at base-
line (interval scaled), education, age (interval scaled),
gender and BMI classes (normal, overweight, obese).
Results
Of 18,000 people 9,944 (55.2%) responded at baseline, of
those 6,688 (67.3%) resp. 6,975 (70.1%) responded at t1
resp. t2. At baseline 1,601 participants had episodic
migraine. The incidence of chronicity was 6.2%. Use of
anti-migraine medication had a protective effect com-
pared to no intake (SA: OR=0.39, 95%-CI=0.19-0.78;
CA: 0.60, 0.22-1.61; T: 0.34, 0.10-1.15). This effect was
stronger for SA than for CA (OR=0.65, 95%-CI=0.28-
1.50). Adjusting for age, gender and BMI classes did not
notably change these results.
Conclusion
Our data indicate that use of acute anti-migraine medi-
cation irrespective of the type (SA, CA, T) reduces the
risk for developing chronic headache.
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